Studies on o-glycosylation of mucin-type proteins and their binding to antibodies, bacterial toxins and viral receptors

Sammanfattning: Carbohydrates are ubiquitous on the surface of all cells in mammals where they are involved in interactions with the surroundings (extracellular matrix), other cells (including self and non - self) and microbes (bacteria and virus). Carbohydrate - protein inte ractions in nature are often mediated via multivalent binding where the combined strength of multiple receptor - ligand interactions results in a binding that is highly specific and strong. In this thesis we have produced proteins that are densely decorated with carbohydrate determinants in order to study the glycosylation capacity of cell lines (paper I) and generate efficient binders of antibodies (paper II), bacterial toxins (paper III) and virus receptors such as the influenza hemagglutinin (paper IV). P - selectin glycoprotein ligand - 1 (PSGL - 1) is a mucin - type protein that is heavily substituted with O - glycans. PSGL - 1 genetically fused to mouse IgG 2b Fc forms a dimeric PSGL - 1/mIgG 2b mucin - type fusion protein. In paper I, PSGL - 1/mIgG 2b was produced in Sf9 ( S podoptera frugiperda ) and Hi - 5 ( Trichoplusia ni ) cell lines. The mucin - type protein was used as a probe to analyze the O - glycosylation capacity of the se cell lines, which today are used for the commercial production of recombinant proteins and vaccine co mponents. Liquid chromatography - mass spectrometry (LC - MS) revealed that the O - glycosylation was more abundant and complex than previously reported which may limit their use for the production of therapeutic proteins. The glycosylation of PSGL - 1/mIgG 2b may be tailored by producing the protein in genetically engineered cell lines. Rational glycan design is achieved by transfecting cells with plasmids encoding PSGL - 1/mIgG 2b together with specific glycosyltransferases that expand the glycosylation capacity of the cells. In paper II, genetically engineered Chinese Hamster Ovary (CHO) cells were used to produce PSGL - 1/mIgG 2b carrying blood group A and B determinants on type 1, 2 and 3 outer core saccharide chains. The multivalent mucins could adsorb chain type - sp ecific anti - A antibodies, which indicate a prospective use of the mucins in immunoadsorption (IA) columns. IA columns are used to remove anti - A and anti - B reactive antibodies prior to organ transplantation across the blood group ABO barrier. In paper III a nd IV, genetically engineered CHO cells were used to produce high affinity binders of Shiga toxin 1 and 2 (Stx1 and Stx2) and avian influenza hemagglutinin (H5) . Biacore biosensor assays indicated that PSGL - 1/mIgG 2b carrying the blood group P1 determinant in multiple copies bound with high affinity to Stx1 and Stx2, while PSGL - 1/mIgG 2b presenting multiple copies of Sia α 2,3Gal on different O - linked cores bound with high affinity to avian influenza H5. It remains to be shown if PSGL - 1/mIgG 2b can competitively inhibit and sterically block toxin and viral attachment to the cell surface. In conclusion, PSGL - 1/mIgG 2b carrying specific carbohydrates is a versatile tool that can be used in a range of applications where the multivalency confers a biologically relevan t binding.